Use of Botulinum Toxin in Orofacial Clinical Practice.
Serrera-Figallo MA, Ruiz-de-León-Hernández G, Torres-Lagares D, Castro-Araya A, Torres-Ferrerosa O, Hernández-Pacheco E, Gutierrez-Perez JL.
Toxins (Basel). 2020 Feb 11;12(2):112. doi: 10.3390/toxins12020112.
Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis.
Yellepeddi VK, Race JA, McFarland MM, Constance JE, Fanaeian E, Murphy NA.
Int J Clin Pharmacol Ther. 2024 Jun;62(6):267-277. doi: 10.5414/CP204538.
The significance of terminal dribbling in men with lower urinary tract symptoms.
Reynard JM, Lim C, Peters TJ, Abrams P.
Br J Urol. 1996 May;77(5):705-10. doi: 10.1046/j.1464-410x.1996.95615.x.
Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion.
Kim JH, Shim JS, Choi H, Moon du G, Lee JG, Kim JJ, Bae JH, Park JY.
BMC Urol. 2015 Aug 29;15:89. doi: 10.1186/s12894-015-0082-x.
Benign prostatic hypertrophy.
O'Brien WM.
Am Fam Physician. 1991 Jul;44(1):162-71.
Metabolic syndrome and male lower urinary tract symptoms.
Ineichen GB, Burkhard FC.
Panminerva Med. 2022 Sep;64(3):329-336. doi: 10.23736/S0031-0808.21.04496-7. Epub 2021 Dec 3.
Bladder-outlet obstruction--assessment of symptoms.
Reynard JM, Abrams P.
World J Urol. 1995;13(1):3-8. doi: 10.1007/BF00182657.
Botulinum Toxin for the Management of Parkinson's Disease: A Systematic Review.
Slouha E, Ibrahim F, Esposito S, Mursuli O, Rezazadah A, Clunes LA, Kollias TF.
Cureus. 2024 Jan 31;16(1):e53309. doi: 10.7759/cureus.53309. eCollection 2024 Jan.
Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.
Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ.
Neurol Clin. 2015 Nov;33(4):889-908. doi: 10.1016/j.ncl.2015.07.010.
Expanding use of botulinum toxin.
Bhidayasiri R, Truong DD.
J Neurol Sci. 2005 Aug 15;235(1-2):1-9. doi: 10.1016/j.jns.2005.04.017.
